Skip to main content

Travelan® Technology

Travelan® contains Bovine Colostrum Powder (BCP) sourced from dairy cows that have been “hyper-immunised” with proprietary Immuron vaccines administered by experienced and qualified veterinarians. These vaccines illicit a strong immune response, resulting in production of very high levels of antibodies, specifically targeting E. coli and the toxins that cause Travellers’ Diarrhoea. The antibodies bind to the E. coli bacteria and the toxins they produce, effectively neutralising them by inhibiting their attachment to the intestinal gut wall reducing inflammation and preventing overgrowth or colonisation of gastrointestinal tract.

Bovine Colostrum also contains natural proteins, minerals, hormones, vitamins and growth factors. BCP also contains lactoperoxidase and lactoferrin which have antimicrobial properties which may aid in the relief of symptoms of minor gastrointestinal disorders.

Proven Protection, Backed by Science

Travelan® has been shown in clinical trials to significantly reduce the risk of Travellers’ Diarrhoea and to alleviate the symptoms of minor gastrointestinal disorders caused by E. coli and other pathogens.

Clinical Evidence Supporting Travelan®

Controlled Human Infection Trials (CHIM)

Travelan® is an antimicrobial which underwent Controlled Human Infection Model (CHIM) studies. These studies were double-blind, placebo-controlled medical trials conducted in Europe and the USA. The trials showed protection of up to 90% against infection with E. coli and the development of Travellers' Diarrhoea. The trials have also shown that people who received Travelan® and subsequently were infected by E. coli had significantly less discomfort and diarrhoea, compared to those who did not receive Travelan®.

Read More

In addition to this research, several controlled clinical trials have confirmed Travelan®'s effectiveness in reducing the incidence of Travellers' Diarrhoea, as well as its safety, tolerability, and the underlying mechanisms of action. These rigorous, double-blind, randomized, placebo-controlled studies were conducted across Europe and the USA, following Good Clinical Practice (GCP) standards. The trials were also approved by regulatory bodies, including the Food and Drug Administration (FDA) in the USA and the Therapeutic Goods Administration (TGA) in Australia.